Ipriflavone prevents the loss of bone mass in pharmacological menopause induced by GnRH-agonists

In a double-blind, placebo controlled study, ipriflavone (600 mg/day, T.D.D.) or identical placebo tablets were given with 500 mg/day of calcium to patients treated with the gonadotropin hormone-releasing hormone agonist (Gn-RH-A) leuproreline acetate, 3.75 mg every 30 days for 6 months. In placebo-treated subjects (n = 39), urinary hydroxyproline excretion and plasma osteocalcin levels snowed a significant (P < 0.01 and P < 0.05, respectively) increase, whereas spine bone density and total body bone density significantly (P < 0.001 and P < 0.05, respectively) decreased after 3 and 6 months of GnRH-A administration. Conversely, in the ipriflavone-treated group (n = 39), no significant difference in bone markers and bone density was evidenced. These data indicate that ipriflavone can restrain the bone remodeling processes and prevent the rapid bone loss that follows medically induced hypogonadism. Similar content being viewed by others

Devogelaer JP, De Deuxchaisnes CN, Donnez J, Thomas K (1987) LHRH analogues and bone loss. Lancet 1498–1501 Matta WH, Shaw RW, Hesp R, Katz D (1987) Hypogonadism induced by luteinising hormone-releasing hormone agonist analogues: effects on bone density in premenopausal women. Br Med J 294:1523–1524 Matta WH, Shaw RW, Hesp R, Evans R (1988) Reversible trabecular bone density loss following induced hypoestrogenism with GnRH analogue buserelin in premenopausal women. Clin Endocrinol 29:45–51 Johansen JS, Riis BJ, Hassager C, Moen M, Jacobson J, Christiansen C (1988) The effect of a gonadotropin-releasing hormone agonist analog (nafarelin) on bone metabolism. J Clin Endocrinol Metab 67:701–706 Dawood MY, Lewis V, Ramos J (1989) Cortical and trabecular bone mineral content in women with endometriosis: effect of gonadotropin-releasing hormone agonist and danazol. Fertil Steril 52:21–26 Jacobson JB (1990) Effects of nafarelin on bone density. Am J Obstet Gynecol 162:591–592 Schalli AR, Jestila KJ, Simon JA (1993) Leuprolide acetate and bone mineral density measured by quantitative digitized radiography. Fertil Steril 59:674–676 Riis BJ, Christiansen C, Johansen JS, Jacobson J (1990) Is it possible to prevent bone loss in young women treated with luteinizing hormone-releasing hormone agonists? J Clin Endocrinol Metab 70:920–924 Surrey ES, Judd HL (1992) Reduction of vasomotor symptoms and bone mineral density loss with combined norethindrone and long-acting gonadotropin-releasing hormone agonist therapy of symptomatic endometriosis: a prospective randomized trial. J Clin Endocrinol Metab 75:558–563 Judd HL (1992) Gonadotropin-releasing hormone agonists: strategies for managing the hypoestrogenic effects of therapy. Am J Obstet Gynecol 166:752–756 West CP, Lumsden MA, Hillier H, Sweeting V, Baird DT (1992) Potential role for medroxyprogesterone acetate as an adjunct to goserelin (Zoladex) in the medical treatment of uterine fibroids. Hum Reprod 7:328–332 Leather AT, Studd JWW, Watson NR, Holland EFN (1987) The prevention of bone loss in young women treated with GnRH analogues with “add-back” estrogen therapy. Obstet Gynecol 81:104–107 Suda A (1987) Effect of parathyroid hormone on parietal bones of rats, and effect of ipriflavone. J Bone Miner Met 5:51–56 Bonucci E, Ballanti P, Martelli A, Mereto E, Brambilla G, Bianco P, Bufalino L (1992) Ipriflavone inhibits osteoclast differentiation in parathyroid transplanted parietal bone of rats. Calcif Tissue Int 50:314–319 Notoya K, Yoshida K, Taketomi S, Yamazaki I, Kumegawa M (1992) Inhibitory effect of ipriflavone on pit formation in mouse unfractionated bone cells. Calcif Tissue Int 51(suppl I):s3-s6 Morita I, Sakaguchi K, Kurachi T, Murota SI (1992) Ipriflavone inhibits murine osteoclast formation in vitro. Calcif Tissue Int 51(suppl 1):s7-s10 Ozawa H, Nakamura H, Me K, Irie M (1992) Histochemical and fine structural study of bone of ipriflavone-treated rats. Calcif Tissue Int 51(suppl 1):s21-s26 Tsuda M, Kitazaki T, Itoh T, Fujita T (1986) The effect of ipriflavone (TC-80) on bone resorption in tissue culture. J Bone Miner Res 1:207–212 Benvenuti S, Tanini A, Frediani U, Bianchi S, Masi L, Casano R, Bufalino L, Serio M, Brandi ML (1991) Effects of ipriflavone and its metabolites on a clonal osteoblastic cell line. J Bone Miner Res 6:987–996 Kakai Y, Kawase T, Nakano T, Mikuni-Takagaki Y, Saito S (1992) Effect of ipriflavone and estrogen on the differentiation and proliferation of osteogenic cells. Calcif Tissue Int 51(suppl 1):s11-s15 Notoya K, Tsukuda R, Yoshida K, Taketomi S (1992) Stimulatory effect of ipriflavone on formation of bone-like tissue in rat bone marrow stromal cell culture. Calcif Tissue Int 51(suppl 1):s16-s20 Shino A, Matsuo T, Tsuda M, Yamazaki I, Tsukuda R, Kitazaki T, Shiota K, Yoshida K (1986) Effect of ipriflavone on bone and mineral metabolism in the streptozotocin diabetic rats. J Bone Miner Met 3:27–37 Yamazaki I, Shino A, Tsukuda R (1986) Effect of ipriflavone on osteoporosis induced by ovariectomy in rats. J Bone Miner Met 3:205–210 Yamazaki I, Shino A, Shimizu Y, Tsukuda R, Shirakawa Y, Kinoshita M (1986) Effect of ipriflavone on glucocorticoidinduced osteoporosis in rats. Life Sci 38:951–958 Melis GB, Paoletti AM, Cagnacci A, Bufalino L, Spinetti A, Gambacciani M, Fioretti P (1992) Lack of any estrogenic effect of ipriflavone in postmenopausal women. J Endocrinol Invest 15:755–761 Newman RE, Logan MA (1950) The determination of hydroxyproline. J Biol Chem 184:299–303 Giordani R, Lucchetti A, Nicollini A, Fiochi U (1983) La determinazione dell’idrossiprolina urinaria: confronto fra due metodi. Bollettino della Società Medico-Chirurgica Pisana 4: 1–3 Gambacciani M, Spinetti A, Cappagli B, Taponeco F, Felipetto R, Parrini D, Cappelli N, Fioretti P (1993) Effects of ipriflavone administration on bone mass and metabolism in ovariectomized women. J Endocrinol Invest 16:333–337 Agnusdei D, Zacchei F, Bigazzi S, Cepollaro C, Nardi P, Montagnani M, Gennari C (1989) Metabolic and clinical effects of ipriflavone in established post-menopausal osteoporosis. Drugs Exp Clin Res XV(2):97–104 Agnusdei D, Camporeale A, Zacchei F, Gennari C, Baroni MC, Costi D, Biondi M, Passeri M, Ciacca A, Sbrenna C, Falsettini E, Ventura A (1992) Effects of ipriflavone on bone mass and bone remodeling in patients with established postmenopausal osteoporosis. Curr Ther Res 51:82–91 Passeri M, Biondi M, Costi D, Dall’Aglio E, Pedrazzoni M, Bufalino L, Castiglione GN, Abate G (1995) Effects of 2-year therapy with ipriflavone in elderly women with established osteoporosis. Ital J Mineral Electrolyte Metab 9:137–144 Author information Authors and Affiliations Rights and permissions About this article Cite this article Gambacciani, M., Cappagli, B., Piaggesi, L. et al. Ipriflavone prevents the loss of bone mass in pharmacological menopause induced by GnRH-agonists. Calcif Tissue Int 61 (Suppl 1), S15–S18 (1997). https://doi.org/10.1007/s002239900379 Issue date: DOI: https://doi.org/10.1007/s002239900379